US 20200040047A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2020/0040047 A1**

SÖLLNER et al. (43) **Pub. Date: Feb. 6, 2020**

(54) **INTERACTION OF DRAXIN AND Y-NETRINS**

(71) Applicant: **Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.**, Muenchen (DE)

(72) Inventors: **Christian SÖLLNER**, Nürtingen (DE); **Xuefan GAO**, Tübingen (DE); **Christiane NÜSSLEIN-VOLHARD**, Tübingen-Bebenhausen (DE)

(73) Assignee: **Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.**, Muenchen (DE)

(21) Appl. No.: **16/553,536**

(22) Filed: **Aug. 28, 2019**

Related U.S. Application Data

(62) Division of application No. 15/113,878, filed on Jul. 25, 2016, now Pat. No. 10,435,442, filed as application No. PCT/EP2015/051088 on Jan. 21, 2015.

(60) Provisional application No. 62/049,643, filed on Sep. 12, 2014.

(30) **Foreign Application Priority Data**

Jan. 23, 2014 (EP) 14152341.5

Publication Classification

(51) **Int. Cl.**

C07K 14/47	(2006.01)
C07K 14/475	(2006.01)
C07K 16/18	(2006.01)
C07K 14/46	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 14/4703*** (2013.01); ***C07K 14/475*** (2013.01); ***C07K 16/18*** (2013.01); *A61K 38/00* (2013.01); ***C07K 14/47*** (2013.01); *C07K 2319/30* (2013.01); ***C07K 14/461*** (2013.01)

(57) **ABSTRACT**

This invention relates to extracellular protein-protein interactions and their possible therapeutic uses. More particularly, this invention describes the interaction between Draxin, particularly fragments binding to γ-Netrins comprising SEQ ID NO.:1, 2 or 3, and variants thereof, with γ-Netrins, and the use of this interaction to disrupt γ-Netrin/Netrin receptor interactions. The invention also relates to diagnostic and/or therapeutic uses of Draxin or fragments or variants thereof, as well as to an antibody against Draxin inhibiting binding of Draxin to γ-Netrins. Further, the invention relates to fragments of γ-Netrins, in particular Draxin-binding Netrin1-fragments comprising SEQ ID NO.: 51 and variants thereof, as well as to an antibody against γ-Netrins inhibiting binding of γ-Netrins to Netrin receptors.

Specification includes a Sequence Listing.